SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
Open accessAbstract
This cohort study examines antibody responses in infection-naive and previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The different antibody kinetics between recovered and vaccinated people may explain the lower incidence of breakthrough infection among previously infected people than among vaccinated people.
“This striking difference in antibody kinetics between convalescent persons and vaccinated persons may be the reason for the substantially lower incidence of breakthrough infection among previously infected persons than among vaccinated persons.24,25”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [24]
Taken together, evidence from this study and others indicates that previously infected people have better long-term humoral response and vaccine effectiveness than recipients of two vaccine doses.
“Overall, the accumulating evidence from our study and others22-25 shows that long-term humoral response and vaccine effectiveness in previously infected persons were superior to that in recipients of two doses of vaccine.”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369 · see citing works
Prendecki, M., Clarke, C., Brown, J., Cox, A., Gleeson, S., Guckian, M., Randell, P., Pria, A. D., Lightstone, L., Xu, X.-N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00502-x · Cited by 271 · see citing works
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
Bradley, T., Grundberg, E., Selvarangan, R., LeMaster, C., Fraley, E., Banerjee, D., Belden, B., Louiselle, D. A., Nolte, N., Biswell, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102051 · Cited by 152 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works
- Authors
- Anderson, M., Stec, M., Rewane, A., Landay, A., Cloherty, G., & Moy, J.
- Affiliations
- Abbott (United States) (US)
- Rush University Medical Center (US)
- Corresponding author
- Moy, James
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2021-08-06
- Volume
- 4
- Issue
- 8
- Pages
- e2119741
- ISSN
- 2574-3805 (ISSN-L)
- PMC
- PMC8346938
- OpenAlex
- W3192243977
- Cited by
- 47
- References
- 4
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 8 · 2022: 24 · 2021: 8
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- JAMA Network Open (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Abbott Diagnostics
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- SARS-CoV-2, BNT162b2, COVID-19 vaccination, antibody response, previously infected individuals, vaccine dosing, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adult, Antibodies, Viral, Antibody Formation, Female, Humans, Male, Middle Aged, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
